Uncovering the Roles of MicroRNAs in Major Depressive Disorder: From Candidate Diagnostic Biomarkers to Treatment Response Indicators.
Claudia HomoroganDiana NituscaEdward SeclamanVirgil EnatescuCatalin MarianPublished in: Life (Basel, Switzerland) (2021)
Major depressive disorder (MDD) is a recurrent debilitating illness that represents a major health burden due to its increasing worldwide prevalence, unclear pathological mechanism, nonresponsive treatment, and lack of reliable and specific diagnostic biomarkers. Recently, microRNA species (miRs) have gained particular interest because they have the ability to post-transcriptionally regulate gene expression by modulating mRNA stability and translation in a cohesive fashion. By regulating entire genetic circuitries, miRs have been shown to have dysregulated expression levels in blood samples from MDD patients, when compared to healthy subjects. In addition, antidepressant treatment (AD) also appears to alter the expression pattern of several miRs. Therefore, we critically and systematically reviewed herein the studies assessing the potential biomarker role of several candidate miRs for MDD, as well as treatment response monitoring indicators, in order to enrich the current knowledge and facilitate possible diagnostic biomarker development for MDD, which could aid in reducing both patients' burden and open novel avenues toward a better understanding of MDD neurobiology.
Keyphrases
- major depressive disorder
- bipolar disorder
- end stage renal disease
- gene expression
- chronic kidney disease
- ejection fraction
- newly diagnosed
- healthcare
- poor prognosis
- risk factors
- prognostic factors
- minimally invasive
- public health
- risk assessment
- genome wide
- health information
- patient reported outcomes
- social media
- combination therapy
- copy number
- human health
- patient reported